New anti-tumor targets and corresponding new anti-tumor agents or means are: targeting cell signal transduction molecules, including protein tyrosine kinase inhibitors, farnesyltransferase (FTase) inhibitors, MAPK signaling pathway inhibitors, and cell cycle regulators.Targeting neovascularization: neovascularization inhibitors;To reduce the detachment, adhesion and basement membrane degradation of cancer cells: anti-metastasis drugs;Targeting telomerase: telomerase inhibitor;Drug resistance to tumor cells: drug resistance reversal agent;Promoting the mature differentiation of malignant cells: differentiation inducers;Specific killing of cancer cells :(antibody or toxin) directed therapy;Enhance the efficacy of radiotherapy and chemotherapy: tumor treatment sensitizers;Enhance or regulate collective immune function: biological response modulator;For oncogenes and tumor suppressor genes: gene therapy - introduction of wild-type tumor suppressor genes, suicide genes, anti-drug resistance genes and antisense oligonucleotides, tumor genetic engineering tumor bacteria.
Highlights
The global Antineoplastic Agents market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Antineoplastic Agents is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Antineoplastic Agents is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Antineoplastic Agents in Plant Medicine is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Antineoplastic Agents include BMS, MSD, Johnson & Johnson, Pfizer, AstraZeneca, Novartis, Sanofi, Celgene and Roche, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antineoplastic Agents, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antineoplastic Agents.
The Antineoplastic Agents market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antineoplastic Agents market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antineoplastic Agents companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
BMS
MSD
Johnson & Johnson
Pfizer
AstraZeneca
Novartis
Sanofi
Celgene
Roche
Lilly
Bayer
Abraxis
Gilead
Wto-Day Order Pharmaceutical
Sinopharm
Shandong Lvye Pharmaceutical
CTTQ
Jiangsu Hengrui Pharmaceutical
Qilu Pharmaceutical
Baekdu Mountain Pharmaceutical
Baida Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Hainan Chang'an International Pharmaceutical
Zhejiang Kanglaite Pharmaceutical
Shandong New Era Pharmaceutical
Liaoning Novino Pharmaceutical
Maanshan Fengyuan Pharmaceutical
Meiluo Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Zhejiang Yatai Pharmaceutical
Tesaro (GSK)
Eisai
Biogen Idec
Teva
AbbVie
Segment by Type
by Treatment Means
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy (Biologic Therapy)
Others
by Dosage Form
Injection
Tablets
Capsule
Suppository
Granules
Implant
其他
by Nature of the Drug
Pharmaceutical Chemicals
Biological Medicine
Natural Product
Segment by Application
Plant Medicine
Hormone
Platinum Compounds
Metabolism Of Drug Resistance
Targeting Small Molecules
Drugs For Cancer
Antibiotic
Alkylating Agent
Chemoradiotherapy Protectant
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antineoplastic Agents companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Treatment Means
1.2.1 Global Antineoplastic Agents Market Size Growth Rate by Treatment Means: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Hormonal Therapy (Biologic Therapy)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Antineoplastic Agents Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Plant Medicine
1.3.3 Hormone
1.3.4 Platinum Compounds
1.3.5 Metabolism Of Drug Resistance
1.3.6 Targeting Small Molecules
1.3.7 Drugs For Cancer
1.3.8 Antibiotic
1.3.9 Alkylating Agent
1.3.10 Chemoradiotherapy Protectant
1.3.11 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antineoplastic Agents Market Perspective (2018-2029)
2.2 Antineoplastic Agents Growth Trends by Region
2.2.1 Global Antineoplastic Agents Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antineoplastic Agents Historic Market Size by Region (2018-2023)
2.2.3 Antineoplastic Agents Forecasted Market Size by Region (2024-2029)
2.3 Antineoplastic Agents Market Dynamics
2.3.1 Antineoplastic Agents Industry Trends
2.3.2 Antineoplastic Agents Market Drivers
2.3.3 Antineoplastic Agents Market Challenges
2.3.4 Antineoplastic Agents Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antineoplastic Agents Players by Revenue
3.1.1 Global Top Antineoplastic Agents Players by Revenue (2018-2023)
3.1.2 Global Antineoplastic Agents Revenue Market Share by Players (2018-2023)
3.2 Global Antineoplastic Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antineoplastic Agents Revenue
3.4 Global Antineoplastic Agents Market Concentration Ratio
3.4.1 Global Antineoplastic Agents Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antineoplastic Agents Revenue in 2022
3.5 Antineoplastic Agents Key Players Head office and Area Served
3.6 Key Players Antineoplastic Agents Product Solution and Service
3.7 Date of Enter into Antineoplastic Agents Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antineoplastic Agents Breakdown Data by Type
4.1 Global Antineoplastic Agents Historic Market Size by Type (2018-2023)
4.2 Global Antineoplastic Agents Forecasted Market Size by Type (2024-2029)
5 Antineoplastic Agents Breakdown Data by Application
5.1 Global Antineoplastic Agents Historic Market Size by Application (2018-2023)
5.2 Global Antineoplastic Agents Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Antineoplastic Agents Market Size (2018-2029)
6.2 North America Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Antineoplastic Agents Market Size by Country (2018-2023)
6.4 North America Antineoplastic Agents Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antineoplastic Agents Market Size (2018-2029)
7.2 Europe Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Antineoplastic Agents Market Size by Country (2018-2023)
7.4 Europe Antineoplastic Agents Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antineoplastic Agents Market Size (2018-2029)
8.2 Asia-Pacific Antineoplastic Agents Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Antineoplastic Agents Market Size by Region (2018-2023)
8.4 Asia-Pacific Antineoplastic Agents Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antineoplastic Agents Market Size (2018-2029)
9.2 Latin America Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Antineoplastic Agents Market Size by Country (2018-2023)
9.4 Latin America Antineoplastic Agents Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antineoplastic Agents Market Size (2018-2029)
10.2 Middle East & Africa Antineoplastic Agents Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Antineoplastic Agents Market Size by Country (2018-2023)
10.4 Middle East & Africa Antineoplastic Agents Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BMS
11.1.1 BMS Company Detail
11.1.2 BMS Business Overview
11.1.3 BMS Antineoplastic Agents Introduction
11.1.4 BMS Revenue in Antineoplastic Agents Business (2018-2023)
11.1.5 BMS Recent Development
11.2 MSD
11.2.1 MSD Company Detail
11.2.2 MSD Business Overview
11.2.3 MSD Antineoplastic Agents Introduction
11.2.4 MSD Revenue in Antineoplastic Agents Business (2018-2023)
11.2.5 MSD Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Antineoplastic Agents Introduction
11.3.4 Johnson & Johnson Revenue in Antineoplastic Agents Business (2018-2023)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Antineoplastic Agents Introduction
11.4.4 Pfizer Revenue in Antineoplastic Agents Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Antineoplastic Agents Introduction
11.5.4 AstraZeneca Revenue in Antineoplastic Agents Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Antineoplastic Agents Introduction
11.6.4 Novartis Revenue in Antineoplastic Agents Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Antineoplastic Agents Introduction
11.7.4 Sanofi Revenue in Antineoplastic Agents Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 Celgene
11.8.1 Celgene Company Detail
11.8.2 Celgene Business Overview
11.8.3 Celgene Antineoplastic Agents Introduction
11.8.4 Celgene Revenue in Antineoplastic Agents Business (2018-2023)
11.8.5 Celgene Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Antineoplastic Agents Introduction
11.9.4 Roche Revenue in Antineoplastic Agents Business (2018-2023)
11.9.5 Roche Recent Development
11.10 Lilly
11.10.1 Lilly Company Detail
11.10.2 Lilly Business Overview
11.10.3 Lilly Antineoplastic Agents Introduction
11.10.4 Lilly Revenue in Antineoplastic Agents Business (2018-2023)
11.10.5 Lilly Recent Development
11.11 Bayer
11.11.1 Bayer Company Detail
11.11.2 Bayer Business Overview
11.11.3 Bayer Antineoplastic Agents Introduction
11.11.4 Bayer Revenue in Antineoplastic Agents Business (2018-2023)
11.11.5 Bayer Recent Development
11.12 Abraxis
11.12.1 Abraxis Company Detail
11.12.2 Abraxis Business Overview
11.12.3 Abraxis Antineoplastic Agents Introduction
11.12.4 Abraxis Revenue in Antineoplastic Agents Business (2018-2023)
11.12.5 Abraxis Recent Development
11.13 Gilead
11.13.1 Gilead Company Detail
11.13.2 Gilead Business Overview
11.13.3 Gilead Antineoplastic Agents Introduction
11.13.4 Gilead Revenue in Antineoplastic Agents Business (2018-2023)
11.13.5 Gilead Recent Development
11.14 Wto-Day Order Pharmaceutical
11.14.1 Wto-Day Order Pharmaceutical Company Detail
11.14.2 Wto-Day Order Pharmaceutical Business Overview
11.14.3 Wto-Day Order Pharmaceutical Antineoplastic Agents Introduction
11.14.4 Wto-Day Order Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.14.5 Wto-Day Order Pharmaceutical Recent Development
11.15 Sinopharm
11.15.1 Sinopharm Company Detail
11.15.2 Sinopharm Business Overview
11.15.3 Sinopharm Antineoplastic Agents Introduction
11.15.4 Sinopharm Revenue in Antineoplastic Agents Business (2018-2023)
11.15.5 Sinopharm Recent Development
11.16 Shandong Lvye Pharmaceutical
11.16.1 Shandong Lvye Pharmaceutical Company Detail
11.16.2 Shandong Lvye Pharmaceutical Business Overview
11.16.3 Shandong Lvye Pharmaceutical Antineoplastic Agents Introduction
11.16.4 Shandong Lvye Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.16.5 Shandong Lvye Pharmaceutical Recent Development
11.17 CTTQ
11.17.1 CTTQ Company Detail
11.17.2 CTTQ Business Overview
11.17.3 CTTQ Antineoplastic Agents Introduction
11.17.4 CTTQ Revenue in Antineoplastic Agents Business (2018-2023)
11.17.5 CTTQ Recent Development
11.18 Jiangsu Hengrui Pharmaceutical
11.18.1 Jiangsu Hengrui Pharmaceutical Company Detail
11.18.2 Jiangsu Hengrui Pharmaceutical Business Overview
11.18.3 Jiangsu Hengrui Pharmaceutical Antineoplastic Agents Introduction
11.18.4 Jiangsu Hengrui Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.18.5 Jiangsu Hengrui Pharmaceutical Recent Development
11.19 Qilu Pharmaceutical
11.19.1 Qilu Pharmaceutical Company Detail
11.19.2 Qilu Pharmaceutical Business Overview
11.19.3 Qilu Pharmaceutical Antineoplastic Agents Introduction
11.19.4 Qilu Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.19.5 Qilu Pharmaceutical Recent Development
11.20 Baekdu Mountain Pharmaceutical
11.20.1 Baekdu Mountain Pharmaceutical Company Detail
11.20.2 Baekdu Mountain Pharmaceutical Business Overview
11.20.3 Baekdu Mountain Pharmaceutical Antineoplastic Agents Introduction
11.20.4 Baekdu Mountain Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.20.5 Baekdu Mountain Pharmaceutical Recent Development
11.21 Baida Pharmaceutical
11.21.1 Baida Pharmaceutical Company Detail
11.21.2 Baida Pharmaceutical Business Overview
11.21.3 Baida Pharmaceutical Antineoplastic Agents Introduction
11.21.4 Baida Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.21.5 Baida Pharmaceutical Recent Development
11.22 Jiangsu Haosen Pharmaceutical Group
11.22.1 Jiangsu Haosen Pharmaceutical Group Company Detail
11.22.2 Jiangsu Haosen Pharmaceutical Group Business Overview
11.22.3 Jiangsu Haosen Pharmaceutical Group Antineoplastic Agents Introduction
11.22.4 Jiangsu Haosen Pharmaceutical Group Revenue in Antineoplastic Agents Business (2018-2023)
11.22.5 Jiangsu Haosen Pharmaceutical Group Recent Development
11.23 Hainan Chang'an International Pharmaceutical
11.23.1 Hainan Chang'an International Pharmaceutical Company Detail
11.23.2 Hainan Chang'an International Pharmaceutical Business Overview
11.23.3 Hainan Chang'an International Pharmaceutical Antineoplastic Agents Introduction
11.23.4 Hainan Chang'an International Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.23.5 Hainan Chang'an International Pharmaceutical Recent Development
11.24 Zhejiang Kanglaite Pharmaceutical
11.24.1 Zhejiang Kanglaite Pharmaceutical Company Detail
11.24.2 Zhejiang Kanglaite Pharmaceutical Business Overview
11.24.3 Zhejiang Kanglaite Pharmaceutical Antineoplastic Agents Introduction
11.24.4 Zhejiang Kanglaite Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.24.5 Zhejiang Kanglaite Pharmaceutical Recent Development
11.25 Shandong New Era Pharmaceutical
11.25.1 Shandong New Era Pharmaceutical Company Detail
11.25.2 Shandong New Era Pharmaceutical Business Overview
11.25.3 Shandong New Era Pharmaceutical Antineoplastic Agents Introduction
11.25.4 Shandong New Era Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.25.5 Shandong New Era Pharmaceutical Recent Development
11.26 Liaoning Novino Pharmaceutical
11.26.1 Liaoning Novino Pharmaceutical Company Detail
11.26.2 Liaoning Novino Pharmaceutical Business Overview
11.26.3 Liaoning Novino Pharmaceutical Antineoplastic Agents Introduction
11.26.4 Liaoning Novino Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.26.5 Liaoning Novino Pharmaceutical Recent Development
11.27 Maanshan Fengyuan Pharmaceutical
11.27.1 Maanshan Fengyuan Pharmaceutical Company Detail
11.27.2 Maanshan Fengyuan Pharmaceutical Business Overview
11.27.3 Maanshan Fengyuan Pharmaceutical Antineoplastic Agents Introduction
11.27.4 Maanshan Fengyuan Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.27.5 Maanshan Fengyuan Pharmaceutical Recent Development
11.28 Meiluo Pharmaceutical
11.28.1 Meiluo Pharmaceutical Company Detail
11.28.2 Meiluo Pharmaceutical Business Overview
11.28.3 Meiluo Pharmaceutical Antineoplastic Agents Introduction
11.28.4 Meiluo Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.28.5 Meiluo Pharmaceutical Recent Development
11.29 Shandong Luoxin Pharmaceutical Group
11.29.1 Shandong Luoxin Pharmaceutical Group Company Detail
11.29.2 Shandong Luoxin Pharmaceutical Group Business Overview
11.29.3 Shandong Luoxin Pharmaceutical Group Antineoplastic Agents Introduction
11.29.4 Shandong Luoxin Pharmaceutical Group Revenue in Antineoplastic Agents Business (2018-2023)
11.29.5 Shandong Luoxin Pharmaceutical Group Recent Development
11.30 Zhejiang Yatai Pharmaceutical
11.30.1 Zhejiang Yatai Pharmaceutical Company Detail
11.30.2 Zhejiang Yatai Pharmaceutical Business Overview
11.30.3 Zhejiang Yatai Pharmaceutical Antineoplastic Agents Introduction
11.30.4 Zhejiang Yatai Pharmaceutical Revenue in Antineoplastic Agents Business (2018-2023)
11.30.5 Zhejiang Yatai Pharmaceutical Recent Development
11.31 Tesaro (GSK)
11.31.1 Tesaro (GSK) Company Detail
11.31.2 Tesaro (GSK) Business Overview
11.31.3 Tesaro (GSK) Antineoplastic Agents Introduction
11.31.4 Tesaro (GSK) Revenue in Antineoplastic Agents Business (2018-2023)
11.31.5 Tesaro (GSK) Recent Development
11.32 Eisai
11.32.1 Eisai Company Detail
11.32.2 Eisai Business Overview
11.32.3 Eisai Antineoplastic Agents Introduction
11.32.4 Eisai Revenue in Antineoplastic Agents Business (2018-2023)
11.32.5 Eisai Recent Development
11.33 Biogen Idec
11.33.1 Biogen Idec Company Detail
11.33.2 Biogen Idec Business Overview
11.33.3 Biogen Idec Antineoplastic Agents Introduction
11.33.4 Biogen Idec Revenue in Antineoplastic Agents Business (2018-2023)
11.33.5 Biogen Idec Recent Development
11.34 Teva
11.34.1 Teva Company Detail
11.34.2 Teva Business Overview
11.34.3 Teva Antineoplastic Agents Introduction
11.34.4 Teva Revenue in Antineoplastic Agents Business (2018-2023)
11.34.5 Teva Recent Development
11.35 AbbVie
11.35.1 AbbVie Company Detail
11.35.2 AbbVie Business Overview
11.35.3 AbbVie Antineoplastic Agents Introduction
11.35.4 AbbVie Revenue in Antineoplastic Agents Business (2018-2023)
11.35.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
BMS
MSD
Johnson & Johnson
Pfizer
AstraZeneca
Novartis
Sanofi
Celgene
Roche
Lilly
Bayer
Abraxis
Gilead
Wto-Day Order Pharmaceutical
Sinopharm
Shandong Lvye Pharmaceutical
CTTQ
Jiangsu Hengrui Pharmaceutical
Qilu Pharmaceutical
Baekdu Mountain Pharmaceutical
Baida Pharmaceutical
Jiangsu Haosen Pharmaceutical Group
Hainan Chang'an International Pharmaceutical
Zhejiang Kanglaite Pharmaceutical
Shandong New Era Pharmaceutical
Liaoning Novino Pharmaceutical
Maanshan Fengyuan Pharmaceutical
Meiluo Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Zhejiang Yatai Pharmaceutical
Tesaro (GSK)
Eisai
Biogen Idec
Teva
AbbVie
*If Applicable.